Clinical trials: Rivaroxaban
Atrial Fibrillation
Italian Registry In the Setting of AF Ablation With Rivaroxaban (IRIS)
The aim of IRIS study is to observe the safety and efficacy of Rivaroxaban in subjects undergoing catheter ablation for atrial fibrillation (AF) in real-world clinical practice.
- Trial name
- IRIS (NCT04315974)
- Testing
- Rivaroxaban, Catheter ablation
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Dr Carlo Lavalle
Left Atrial Appendage Thrombosis, Thrombi
Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO
The objective of this study is to assess the efficacy and safety different dosage of rivaroxaban application versus dual antiplatelet therapy after successful closure of left atrial appendage using the LAMBRE device.
- Conditions
- Left Atrial Appendage Thrombosis, Thrombi, Stroke
- Trial name
- NCT04135677
- Testing
- Rivaroxaban, DAPT
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Shanghai Zhongshan Hospital
Coagulation
Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™
The Perosphere ClotChek™ system consists of a hand-held, battery-operated blood coagulation instrument and disposable test cuvettes for use at the point-of-care (POC).
- Trial name
- NCT07012291
- Testing
- Whole Blood Clotting Time
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- Perosphere Technologies Inc.
Non-valvular Atrial Fibrillation (NVAF)
A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin
This is an observational study in which data collected from the past of patients with non-valvular atrial fibrillation (NVAF) is studied.
- Trial name
- RENOVATOR (NCT05022758)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- South Korea
- Volunteers
- 45,000 people
- Sponsor
- Bayer
Portal Vein Thrombosis, Mesenteric Vein Thrombosis
Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study
Anticoagulant therapy is generally recommended for all patients presenting with acute symptomatic splanchnic vein thrombosis, starting with either low-molecular weight heparin (LMWH) or unfractionated heparin and continuing with…
- Conditions
- Portal Vein Thrombosis, Mesenteric Vein Thrombosis, Splenic Vein Thrombosis
- Trial name
- NCT02627053
- Testing
- rivaroxaban
- Where
- 4 sites in Canada, Italy
- Volunteers
- 100 people
- Sponsor
- Università degli Studi dell'Insubria
Venous Thromboembolism, Children Under 2 Years
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
- Trial name
- XAPAEDUS (NCT05900388)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC)
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 850 people
- Sponsor
- Bayer
Atrial Fibrillation, Stroke
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.
- Conditions
- Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
- Trial name
- ARC (NCT01747746)
- Testing
- Rivaroxaban, Warfarin and Enoxaparin
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Cook County Health
Heavy Menstrual Bleeding
Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
Prospective comparison of the incidence of heavy menstrual bleeding (HMB) in women of reproductive age treated with direct oral anticoagulants (DOACs)
- Trial name
- NCT04477837
- Testing
- Apixaban 5 MG, Rivaroxaban 20 MG, Edoxaban 60 MG
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Hypotension
Ambulatory Blood Pressure Monitoring in Rivaroxaban Therapy
One in ten patients on rivaroxaban therapy have dizziness and reductions in blood pressure. The investigators intend to monitor the ambulatory blood pressure of such patients in order to assess whether this is a true haemodynamic…
- Trial name
- NCT02539953
- Testing
- Ambulatory blood pressure monitoring
- Where
- United Kingdom
- Sponsor
- King's College Hospital NHS Trust
Venous Thromboembolism
Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism
Prospective, multicenter observational study, of the effectiveness of a standard of care protocol implemented to enhance home treatment of VTE.
- Trial name
- MATHVTE (NCT03404635)
- Testing
- Apixaban, Rivaroxaban
- Where
- 2 sites in United States
- Volunteers
- 1,300 people
- Sponsor
- Indiana University
Venous Thromboembolism
Statin Use in Patients With Acute VTE
This is a pilot, randomized, open-labelled study. Eligible patients will be enrolled and randomized 1:1 into "anticoagulation" arm or "anticoagulation plus atorvastatin" arm, with atorvastatin given at 40 mg orally daily for 3…
- Trial name
- NCT02331095
- Testing
- Atorvastatin, Anticoagulation Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University
Kawasaki Disease, Pilot Study
Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease
Based on a population pharmacokinetic model-based dose optimization study, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after Kawasaki disease was…
- Conditions
- Kawasaki Disease, Pilot Study, Coronary Artery Aneurysm, Rivaroxaban
- Trial name
- NCT06978439
- Testing
- Rivaroxaban (Xarelto)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Children's Hospital of Fudan University
Anticoagulant-induced Bleeding
DOAC Versus VKA After Cardiac Surgery
Postoperative management of oral anticoagulation is a frequent preoccupation in cardiac surgery, concerning about half of patients.
- Trial name
- DOAC/VKA (NCT04002011)
- Testing
- Warfarin, Dabigatran, Rivaroxaban
- Sponsor
- Laval University
Sickle Cell Anemia, Sickle Cell-Beta0-Thalassemia
The Effect of Rivaroxaban in Sickle Cell Disease
The primary study hypothesis is that inhibition of factor Xa with rivaroxaban will reduce inflammation, coagulation and endothelial cell activation, and improve microvascular blood flow in patients with sickle cell disease (SCD)…
- Trial name
- NCT02072668
- Testing
- rivaroxaban
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of North Carolina, Chapel Hill
Pharmacokinetics, Bioavailability
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
The primary objective of this study is to learn about the relative bioavailability (the extent to which the drug becomes available to the body) and pharmacokinetics (blood levels) of rivaroxaban in healthy participants after…
- Conditions
- Pharmacokinetics, Bioavailability, Healthy Participants
- Trial name
- NCT01464450
- Testing
- Rivaroxaban
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Anticoagulant Adverse Reaction
Precision Medicine Platform for Novel Oral Anticoagulants
The anticoagulants have been developed with new generation for FDA-approved indications including treatment and prevention of venous, pulmonary, and systemic thromboembolism.
- Trial name
- NCT04056143
- Testing
- Pharmacogenomics
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Kaohsiung Medical University
Periprocedural Complication
Periprocedural Direct Oral Anticoagulant Management
Direct oral anticoagulants (DOAC) are a new drug group that has been approved for chronic anticoagulation of patients in atrial fibrillation or suffering acute thrombosis, between others.
- Trial name
- RA-ACOD (NCT03182218)
- Testing
- Direct oral anticoagulant
- Where
- 30 sites in Spain
- Volunteers
- 1,100 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Atrial Fibrillation, Atrial Flutter
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-AF (NCT03129490)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 38 sites in Denmark
- Volunteers
- 11,000 people
- Sponsor
- Herlev and Gentofte Hospital
Pulmonary Embolism
The PEERLESS II Study
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
- Trial name
- NCT06055920
- Testing
- FlowTriever System, Anticoagulation Agents
- Where
- 72 sites in United States, Belgium and 6 more
- Volunteers
- 1,200 people
- Sponsor
- Inari Medical
Atrial Fibrillation, Deep Vein Thrombosis
An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®).
This study aims to evaluate the use of rivaroxaban and its short term safety when used by patients for the new indications of prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treatment…
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- ROSE (NCT01871194)
- Where
- United Kingdom
- Volunteers
- 3,400 people
- Sponsor
- Professor Saad Shakir